{"id":6838,"date":"2024-03-07T01:52:22","date_gmt":"2024-03-07T01:52:22","guid":{"rendered":"https:\/\/economicherald.net\/?p=6838"},"modified":"2024-03-07T01:52:22","modified_gmt":"2024-03-07T01:52:22","slug":"asx-health-stocks-immuron-leaps-80pc-after-announcing-that-travelan-trials-will-move-to-phase-3","status":"publish","type":"post","link":"https:\/\/economicherald.net\/?p=6838","title":{"rendered":"ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3"},"content":{"rendered":"<p>Immuron jumps 80pc Travelan shown to be effective<br \/>\nThe trial is now set to to progress to Phase 3<br \/>\nDoctor Care Anywhere announces a new, permanent CEO<\/p>\n<p>\u00a0<\/p>\n<h2>Immuron almost doubles on Travelan results<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/immuron-imc\/\">Immuron (ASX:IMC)<\/a><\/strong> jumped by over 80% this morning after announcing interim topline results confirming the efficacy of <strong>Travelan<\/strong> in preventing diarrhoea following <strong>enterotoxigenic Escherichia coli (ETEC)<\/strong>.<\/p>\n<p>The Phase 2 study on 60 patients show that a single daily dose of Travelan is <strong>36.4% effective in the prevention of moderate to severe diarrhoea<\/strong> induced by ETEC, when compared to the placebo group in the study.<\/p>\n<p>Around 66.7% protective efficacy against <strong>ETEC-induced severe diarrhoea<\/strong> was also observed in the patients taking Travelan, compared to the placebo group (secondary endpoint).<\/p>\n<p>Results also demonstrated a 83.3% statistically significant reduction in the number of subjects in the Travelan group requiring early antibiotic treatment post-ETEC, compared to the placebo group.<\/p>\n<p>This was particularly significant as all (100%) taking placebo required IV fluids post-ETEC challenge.<\/p>\n<p>Finally, there was 55.6% reduction in the number of patients experiencing adverse events associated with the ETEC challenge observed in the Travelan group, compared to the placebo group.<\/p>\n<p>Immuron says these results will support the progress of Travelan into a Phase 3 trial.<\/p>\n<p>\u00a0<\/p>\n<h2>DOC announces new CEO<\/h2>\n<p><strong><a href=\"https:\/\/stockhead.com.au\/company\/doctor-care-anywhere-group-plc-doc\/\">Doctor Care Anywhere (ASX:DOC)<\/a><\/strong> surged as much as +11% this morning after announcing the appointment of <strong>Ben Kent as its new CEO<\/strong>, following a successful year as interim CEO.<\/p>\n<p>He also joins the board of directors as an executive director.<\/p>\n<p>Seema Sangar has also been appointed as CFO, having previously held finance director roles at Equiniti Group plc and Avast Plc.<\/p>\n<p>DOC is one of the UK\u2019s largest private providers of telehealth services.<\/p>\n<p>The company lost its former CEO, Bayju Thakar, in late 2022 before Kent took over as interim CEO in March 2023.<\/p>\n<p>\u00a0<\/p>\n<h2>Share prices today:<\/h2>\n<p>\u00a0<\/p>\n\n<p><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\">\ufeff<\/span><span class=\"mce_SELRES_start\"><\/span>\u00a0<br \/>\n<span class=\"et_bloom_bottom_trigger\"><\/span><\/p>\n<p>The post <a href=\"https:\/\/stockhead.com.au\/health\/asx-health-stocks-immuron-leaps-80pc-after-announcing-that-travelan-trials-will-move-to-phase-3\/\">ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3<\/a> appeared first on <a href=\"https:\/\/stockhead.com.au\/\">Stockhead<\/a>.<\/p>","protected":false},"excerpt":{"rendered":"<p>Immuron jumps 80pc Travelan shown to be effective The trial is now set to to progress to Phase 3 Doctor Care Anywhere announces a new, <a href=\"https:\/\/economicherald.net\/?p=6838\" class=\"read-more-link\">[more&#8230;]<\/a><\/p>\n","protected":false},"author":0,"featured_media":6839,"comment_status":"","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[],"class_list":["post-6838","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3 - Economic Herald<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicherald.net\/?p=6838\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3 - Economic Herald\" \/>\n<meta property=\"og:description\" content=\"Immuron jumps 80pc Travelan shown to be effective The trial is now set to to progress to Phase 3 Doctor Care Anywhere announces a new, [more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicherald.net\/?p=6838\" \/>\n<meta property=\"og:site_name\" content=\"Economic Herald\" \/>\n<meta property=\"article:published_time\" content=\"2024-03-07T01:52:22+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6838#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6838\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3\",\"datePublished\":\"2024-03-07T01:52:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6838\"},\"wordCount\":331,\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6838#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/Immuron-leaps-80pc-after-announcing-Phase-2-results-for-Travelan.-Picture-Getty-USVBez.jpeg\",\"articleSection\":[\"Finance\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6838\",\"url\":\"https:\\\/\\\/economicherald.net\\\/?p=6838\",\"name\":\"ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3 - Economic Herald\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6838#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6838#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/Immuron-leaps-80pc-after-announcing-Phase-2-results-for-Travelan.-Picture-Getty-USVBez.jpeg\",\"datePublished\":\"2024-03-07T01:52:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6838#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/economicherald.net\\\/?p=6838\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6838#primaryimage\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/Immuron-leaps-80pc-after-announcing-Phase-2-results-for-Travelan.-Picture-Getty-USVBez.jpeg\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2024\\\/03\\\/Immuron-leaps-80pc-after-announcing-Phase-2-results-for-Travelan.-Picture-Getty-USVBez.jpeg\",\"width\":1200,\"height\":675},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/?p=6838#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/economicherald.net\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#website\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"name\":\"Economic Herald\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/economicherald.net\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#organization\",\"name\":\"Economic Herald\",\"url\":\"https:\\\/\\\/economicherald.net\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"contentUrl\":\"https:\\\/\\\/economicherald.net\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/cropped-cropped-economicheraldlogo-1.png\",\"width\":850,\"height\":760,\"caption\":\"Economic Herald\"},\"image\":{\"@id\":\"https:\\\/\\\/economicherald.net\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3 - Economic Herald","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicherald.net\/?p=6838","og_locale":"en_US","og_type":"article","og_title":"ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3 - Economic Herald","og_description":"Immuron jumps 80pc Travelan shown to be effective The trial is now set to to progress to Phase 3 Doctor Care Anywhere announces a new, [more...]","og_url":"https:\/\/economicherald.net\/?p=6838","og_site_name":"Economic Herald","article_published_time":"2024-03-07T01:52:22+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicherald.net\/?p=6838#article","isPartOf":{"@id":"https:\/\/economicherald.net\/?p=6838"},"author":{"name":"","@id":""},"headline":"ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3","datePublished":"2024-03-07T01:52:22+00:00","mainEntityOfPage":{"@id":"https:\/\/economicherald.net\/?p=6838"},"wordCount":331,"publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"image":{"@id":"https:\/\/economicherald.net\/?p=6838#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/03\/Immuron-leaps-80pc-after-announcing-Phase-2-results-for-Travelan.-Picture-Getty-USVBez.jpeg","articleSection":["Finance"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicherald.net\/?p=6838","url":"https:\/\/economicherald.net\/?p=6838","name":"ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3 - Economic Herald","isPartOf":{"@id":"https:\/\/economicherald.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicherald.net\/?p=6838#primaryimage"},"image":{"@id":"https:\/\/economicherald.net\/?p=6838#primaryimage"},"thumbnailUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/03\/Immuron-leaps-80pc-after-announcing-Phase-2-results-for-Travelan.-Picture-Getty-USVBez.jpeg","datePublished":"2024-03-07T01:52:22+00:00","breadcrumb":{"@id":"https:\/\/economicherald.net\/?p=6838#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicherald.net\/?p=6838"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/?p=6838#primaryimage","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/03\/Immuron-leaps-80pc-after-announcing-Phase-2-results-for-Travelan.-Picture-Getty-USVBez.jpeg","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2024\/03\/Immuron-leaps-80pc-after-announcing-Phase-2-results-for-Travelan.-Picture-Getty-USVBez.jpeg","width":1200,"height":675},{"@type":"BreadcrumbList","@id":"https:\/\/economicherald.net\/?p=6838#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicherald.net\/"},{"@type":"ListItem","position":2,"name":"ASX Health Stocks: Immuron leaps 80pc after announcing that Travelan trials will move to Phase 3"}]},{"@type":"WebSite","@id":"https:\/\/economicherald.net\/#website","url":"https:\/\/economicherald.net\/","name":"Economic Herald","description":"","publisher":{"@id":"https:\/\/economicherald.net\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicherald.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicherald.net\/#organization","name":"Economic Herald","url":"https:\/\/economicherald.net\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/","url":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","contentUrl":"https:\/\/economicherald.net\/wp-content\/uploads\/2023\/10\/cropped-cropped-economicheraldlogo-1.png","width":850,"height":760,"caption":"Economic Herald"},"image":{"@id":"https:\/\/economicherald.net\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/6838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6838"}],"version-history":[{"count":0,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/posts\/6838\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=\/wp\/v2\/media\/6839"}],"wp:attachment":[{"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6838"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicherald.net\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}